Early treatment with intravenous bisphosphonates at first radiographic evidence of bone lesions in patients with solid tumors or evidence of osteopenia in patients with multiple myeloma can ...

The various regimens for oral and intravenous bisphosphonate use have been developed in a fairly arbitrary manner, and other approaches can be successful. For example, alendronate is commonly ...

Ibandronate is the only bisphosphonate approved for once-monthly oral dosing, because of its particularly long half-life. Other intravenous bisphosphonate formulations have to be infused slowly to ...

Dental extractions and use of dentures have been validated as risk factors for the development of bisphosphonate-related osteonecrosis of the jaw (ONJ) in patients with cancer, according to ...